Phase Study About Feeding Artery Obliteration by Chemoembolization on Survival of Patients With Unresectable Hepatocellular Carcinoma
Subjective angiographic chemoembolization endpoints (SACE) levels were developed to
standardize the embolic endpoints of transarterial chemoembolization (TACE) for
hepatocellular carcinoma (HCC). It determined the antegrade arterial flow and residual tumor
blush as follows: I, normal-normal; II, reduced-reduced; III, reduced-none; IV, none-none.
SACE level II and III indicates intermediate-levels of embolization, whereas IV indicates
overembolization. The aim of this study was to evaluate whether survival of patients who
underwent TACE with unresectable HCC can benefit from intermediate-levels of embolization.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Survival rate of the subjects
Survival rate of the subjects 6 months after TACE
6 months after TACE
Sang Hoon Park, M.D., Ph.D.
Hallym University Medical Center
South Korea: Institutional Review Board